Selangor, 23 Oct 2025 – Reszon Diagnostics International Sdn. Bhd. (“Reszon”), a subsidiary of Hextar Healthcare, manufacturer of innovative rapid diagnostic tests, proudly announces the commercial launch of the RESZON HBsAg Rapid Test (MDA Registration Number: IVDD4340025-214346), a rapid diagnostic solution designed to deliver fast and reliable detection of the Hepatitis B surface antigen (HBsAg) in serum, plasma or whole-blood samples.
This latest launch complements the recently introduced RESZON HCV Rapid Test in September 2025, completing Reszon’s Hepatitis B & C rapid testing range and further strengthening its mission to advance early and accessible hepatitis screening solutions worldwide.
Global Burden of Hepatitis B
Hepatitis B continues to pose a major global health challenge. According to the World Health Organization (WHO), an estimated 254 million people were living with chronic Hepatitis B infection in 2022, with 1.2 million new infections each year and resulting in an estimated 1.1 million deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer). (WHO, 2024)1
Despite the availability of vaccines and treatments, as of 2022, only 13% of people living with chronic Hepatitis B infection had been diagnosed (WHO, Global Hepatitis Report 2024)2.
Many remain undiagnosed, particularly in low and middle-income countries where access to diagnostics is limited.
Who Should Get Tested for Hepatitis B?
- Individuals who suspect they may have been exposed to Hepatitis B
- All pregnant women during each pregnancy, preferably in the first trimester, regardless of vaccination status or history of testing
- Healthcare and emergency response workers exposed to blood or body fluids
- People with multiple sexual partners
- People with elevated liver enzymes
- People undergoing dialysis or with chronic kidney disease
- People with HIV or Hepatitis C
- People who inject drugs (PWID)
- People in prisons and other closed settings
- Migrants from endemic regions
Source: CDC, Clinical Testing and Diagnosis for Hepatitis B; WHO, Hepatitis B Fact Sheet
Why HBV Screening is Important?
More than half of people with hepatitis B are unaware of their infection status, and approximately 50%–70% of people with acute hepatitis B are asymptomatic. Without testing, people with hepatitis B virus (HBV) infection can unknowingly transmit the virus to others (CDC, 2025)3.
Early detection through HBsAg screening plays a critical role in detecting silent carriers, preventing further transmission, linking patients to care and ultimately reducing disease burden.
Strategic Diagnostic Innovation for Hepatitis B
HBsAg is a critical marker for qualitative detection of Hepatitis B Virus (HBV) infection. In line with global efforts to eliminate viral hepatitis as a public-health threat, RESZON HBsAg Rapid Test deploys immunochromatographic assay technology to deliver qualitative detection of HBsAg in just 15-20 minutes, making it an ideal test kit to supports healthcare providers, clinical laboratories and community screening programmes.
Key Features of RESZON HBsAg Rapid Test
- High Accuracy: Sensitivity: 99.3% Specificity: 99.8%
- Fast Results: Delivers results in just 15–20 minutes
- Convenient Testing: Simple to perform with no special equipment required
- Minimal Specimen Volume: Human whole blood, serum & plasma (75 μl)
- Stable Shelf Life: 24 months from date of manufacture, stored at 4–30°C
“With the commercial release of RESZON HBsAg Rapid Test, the company aim to strengthen its role in the global diagnostic ecosystem — helping healthcare professionals act earlier and with confidence,” said Katherine Koay, sales director of Reszon.
Free Sampling Programme
Healthcare professionals and GDPMD distributors are invited to request the e-brochure and FAQ guide, as well as apply for free product sample, to facilitate evaluation and integration into Hepatitis B screening program.
References:
- World Health Organization (WHO) (2025). Hepatitis B Fact Sheet. (Updated 25 July 2025) Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (Accessed 23 October 2025).
- World Health Organization (2024) Global hepatitis report 2024: action for access in low- and middle-income countries. WHO. Available at: https://www.who.int/publications/b/68511 (Accessed: 23 October 2025).
- Centers for Disease Control and Prevention (CDC) (2025). Clinical Testing and Diagnosis for Hepatitis B [Updated 31 Jan 2025] Available at: https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/index.html (Accessed 23 October 2025).
